- Conditions
- Juvenile Idiopathic Arthritis, JIA
- Interventions
- adalimumab, Methotrexate
- Biological · Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 849 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2024
- U.S. locations
- 32
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 28 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 103
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Juvenile Idiopathic Arthritis Associated Uveitis, Uveitis, Anterior
- Interventions
- Adalimumab/Biosimilar
- Biological
- Lead sponsor
- Nisha Acharya
- Other
- Eligibility
- 2 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Sacramento, California • San Francisco, California + 6 more
- Conditions
- Juvenile Idiopathic Arthritis
- Interventions
- Tocilizumab, Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 188 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 10
- States / cities
- Hartford, Connecticut • Washington D.C., District of Columbia • Delray Beach, Florida + 7 more
- Conditions
- Juvenile Idiopathic Arthritis, Rheumatoid Arthritis, Obesity
- Interventions
- Etanercept Optimal dosing
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 2 Years to 65 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Juvenile Idiopathic Arthritis (JIA)
- Interventions
- Active tcVNS, Sham tcVNS
- Device
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 5 Years to 18 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 7
- States / cities
- San Francisco, California • Orlando, Florida • Indianapolis, Indiana + 4 more
- Conditions
- Systemic Juvenile Idiopathic Arthritis (SJIA)
- Interventions
- ACZ885 150 mg (Canakinumab)
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 2 Years to 20 Years
- Enrollment
- 182 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 2
- States / cities
- Los Angeles, California • Columbus, Ohio
- Conditions
- Alcohol Abuse, Drug Abuse
- Interventions
- Brief Intervention
- Behavioral
- Lead sponsor
- Boston Children's Hospital
- Other
- Eligibility
- 14 Years to 18 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Still´s Disease
- Interventions
- MAS825
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 1 Year and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 3
- States / cities
- Cincinnati, Ohio • Portland, Oregon • Salt Lake City, Utah
- Conditions
- Juvenile Idiopathic Arthritis
- Interventions
- Upadacitinib, Tocilizumab
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 1 Year to 17 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 6
- States / cities
- Phoenix, Arizona • Washington D.C., District of Columbia • Valhalla, New York + 3 more
- Conditions
- Arthritis, Juvenile Rheumatoid, Still's Disease, Juvenile Onset
- Interventions
- tocilizumab
- Biological
- Lead sponsor
- Tufts Medical Center
- Other
- Eligibility
- 2 Years to 16 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Juvenile Idiopathic Arthritis, Systemic Lupus Erythematosus, Fibromyalgia
- Interventions
- No Intervention
- Other
- Lead sponsor
- Children's National Research Institute
- Other
- Eligibility
- 5 Years to 21 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Juvenile Idiopathic Arthritis
- Interventions
- Tocilizumab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 1 Year to 17 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 11
- States / cities
- Little Rock, Arkansas • Hartford, Connecticut • Chicago, Illinois + 7 more
- Conditions
- Systemic Juvenile Idiopathic Arthritis
- Interventions
- Canakinumab
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 2 Years to 19 Years
- Enrollment
- 270 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Louisville, Kentucky • Boston, Massachusetts + 3 more
- Conditions
- Juvenile Rheumatoid Arthritis
- Interventions
- Infliximab
- Drug
- Lead sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- NIH
- Eligibility
- Not listed
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2005
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Osteoarthritis, Rheumatoid Arthritis, Other Inflammatory Arthritis, Post-Traumatic Arthritis, Juvenile Rheumatoid Arthritis, Avascular Necrosis
- Interventions
- Total Knee Arthroplasty, Total knee replacement
- Device
- Lead sponsor
- DePuy Orthopaedics
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 149 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2007
- U.S. locations
- 3
- States / cities
- Greensboro, North Carolina • Austin, Texas • Lakewood, Washington
- Conditions
- Arthritis
- Interventions
- Ultrasound imaging
- Device
- Lead sponsor
- Stanford University
- Other
- Eligibility
- Up to 21 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Anterior Uveitis (AU), Birdshot Chorioretinitis, Behcet Disease, Herpes Simplex Virus, Juvenile Idiopathic Arthritis (JIA), Spondyloarthritis (SA), Sarcoidosis, Posterior Vitreous Detachment
- Interventions
- Not listed
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 5 Years to 85 Years
- Enrollment
- 125 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Juvenile Idiopathic Arthritis (JIA)
- Interventions
- allogeneic Hope Biosciences adipose-derived mesenchymal stem cells, Normal Saline Solution 0.9%
- Biological · Other
- Lead sponsor
- Hope Biosciences Research Foundation
- Industry
- Eligibility
- 2 Years to 16 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Sugar Land, Texas
- Conditions
- Arthritis
- Interventions
- Blood Draws for Serum Titers
- Other
- Lead sponsor
- University Hospitals Cleveland Medical Center
- Other
- Eligibility
- 9 Years to 26 Years · Female only
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2014
- U.S. locations
- 4
- States / cities
- Chicago, Illinois • Cleveland, Ohio
- Conditions
- Juvenile Idiopathic Arthritis
- Interventions
- SLEEPSAMRT
- Behavioral
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 8 Years to 13 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Juvenile Idiopathic Arthritis
- Interventions
- Tocilizumab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 2 Years to 18 Years
- Enrollment
- 82 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2021
- U.S. locations
- 9
- States / cities
- Little Rock, Arkansas • Chicago, Illinois • Hackensack, New Jersey + 6 more
- Conditions
- Arthritis, Juvenile Rheumatoid
- Interventions
- Celecoxib, Naproxen
- Drug
- Lead sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 201 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 18
- States / cities
- Tucson, Arizona • Little Rock, Arkansas • San Diego, California + 9 more
- Conditions
- Juvenile Idiopathic Arthritis
- Interventions
- CP-690,550
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 4
- States / cities
- Minneapolis, Minnesota • Cincinnati, Ohio • Portland, Oregon
- Conditions
- Juvenile Rheumatoid Arthritis
- Interventions
- Abatacept, Placebo
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 214 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2011
- U.S. locations
- 10
- States / cities
- Omaha, Nebraska • Livingston, New Jersey • New Hyde Park, New York + 7 more